# IG vs ID Bitter Administration

> **NCT03985865** · PHASE4 · COMPLETED · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 14 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Intragastric quinine hydrochloride
- **DRUG:** Intragastric denatonium benzoate
- **DRUG:** Intragastric placebo
- **DRUG:** Intraduodenal quinine hydrochloride
- **DRUG:** Intraduodenal denatonium benzoate
- **DRUG:** Intraduodenal placebo

## Key facts

- **NCT ID:** NCT03985865
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2018-05-07
- **Final completion:** 2018-05-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03985865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03985865, "IG vs ID Bitter Administration". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03985865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*